{"id":388662,"date":"2020-11-25T13:31:56","date_gmt":"2020-11-25T18:31:56","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388662"},"modified":"2020-11-25T13:31:56","modified_gmt":"2020-11-25T18:31:56","slug":"agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LEXINGTON, Mass., Nov.  25, 2020  (GLOBE NEWSWIRE) &#8212; Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM \u2013 11:15 AM EST.<\/p>\n<p>Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress.<\/p>\n<p>Registration for the webinar can be done in advance at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6-TXFBFlXeEY92Qb0iKMlbGY6AnjVXnCBZcvMMN9YdRa2C5s8YWtgvuikBTqPsBQ9Y_D5iH7em7eslbGLG9dsW-d3HXwJYDQ4IY6QFyjcVMFYVhyvhm9aKEwLx12ncUGQ8ow3bSnZXskggfxrR7C9C2Wm9ur7F-76zAQUrvhX-41t23tbEpHHugkEq2wgCmcJWbWZENxAuxSWbmKPmvEsg1PzlklvaLhh3LDrVYCnzijMYLl2Z0G4Sa8_RCNd9OeeqoLyN5EBn2iodtfUZ9m3BzLljcj1db0ZEmUEt4QmW2QP_5Box5_tFLEGi6ajlB7vgYsqiqPZ0S6sRPHH28ckdq3PGrfuKtv-zmaICUaO-8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/wsw.com\/webcast\/evercore11\/register.aspx?conf=evercore11&amp;page=agen&amp;url=https:\/\/wsw.com\/webcast\/eve<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qUZeMkgTpJ-iDO-dnT1ofatVefAMns5OvCISHvtTWzY8TnujCTzN00tcUUKfTatxDJ2xO2hwgbvafYNd5jl0qH0fuVphpyWKSh7lnt0PIRWjhN9WKvKquWBSrv7BvdfQ7kfTrVUBZ4DIVL8sK4PEH4iq-uszQ1ahzFqs7Bj09IyYLg5ddumzaAUqzMGdlLfdf28Y7nxW1dGvNrHnjBhX0g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">r<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0ebti0bp8Tah7OWYjP4TVzmFuGpirbYFBlPeUztnJAcyLDuq1lGByB4IJo-0S2I3M4d2NFervKrVCWwIp5ad5Hk9H3iNtabowXV11pbQSpo03FYsAHHrULlz2AHRD_robxrqXY-DKAmJnqp8h_YbmE7eNjmsY_xjX24SNG0Qs7mJs9r7cU3xbaMWWfzfoNx8juikifb8BRZmVlrvUS3dBF9dZAJLo5QqWca0zEDRQM4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">core11\/agen\/2321775<\/a>.<\/p>\n<p>A replay will be available after the call on the Events &amp; Presentations page of the Agenus website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6-TXFBFlXeEY92Qb0iKMlTsMC_sxK3q8O0cwocqyKDZF5yHKvpZrtDwsrlCd5guWOs34wO-yasWIHv9aTRsz9-6OO4991efnASWDChinH3TGOAyYj_onu99hbhfZzvsrACZvbyTSHXXTEi5peN8-0Q2yPGzd9ul0pp4fp49MoF9NvXl1zsYFgQJTR6K7lHvp\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/investor.agenusbio.com\/events-and-presentations<\/a>. \u00a0\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>About Agenus<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer. The Company&#8217;s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in\u00a0Lexington, MA.\u00a0For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y7gREDZuFYzZGa5gzj6oK2izsVqwCfA8U0uA-_o-g0kqeBbanMU4tPzzG-bn638-da_sQw9ZiDND_QZUErzJcIryb3EPqph_j7LphSrut3OG0CseWgcsyb_SDwgbxxVHLru_ke6xnbVPGf1s_x01SH9SVZAmRJJqABnhSwQ_nEPCsx1rOmefC4LVrP7ldFNRAQGlBmygpNk1OgPnzF1BQg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.agenusbio.com<\/u><\/a>\u00a0and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Agenus Inc.\u00a0<br \/><\/strong>Caroline Bafundo\u00a0 \u00a0 \u00a0 \u00a0 <br \/>212-994-8209<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jrw1fktexZ5VIBSzBXcmaS3w9uVjSB94skY30RODbyyqrmlDDZ_tNteRMswB7O7yl0IKfxl1kcx0czQ4g056uU5Wh1--1BZFckwVjq6X8CiQQSATun41obByYRs9S7HC\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Caroline.Bafundo@agenusbio.com<\/u><\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/eef8d670-2373-4086-b3d1-c609dc3cdf45\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM \u2013 11:15 AM EST. Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress. Registration for the webinar can be done in advance at https:\/\/wsw.com\/webcast\/evercore11\/register.aspx?conf=evercore11&amp;page=agen&amp;url=https:\/\/wsw.com\/webcast\/evercore11\/agen\/2321775. A replay will be available after the call on the Events &amp; Presentations page of the Agenus website &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM \u2013 11:15 AM EST. Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress. Registration for the webinar can be done in advance at https:\/\/wsw.com\/webcast\/evercore11\/register.aspx?conf=evercore11&amp;page=agen&amp;url=https:\/\/wsw.com\/webcast\/evercore11\/agen\/2321775. A replay will be available after the call on the Events &amp; Presentations page of the Agenus website &hellip; Continue reading &quot;Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T18:31:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference\",\"datePublished\":\"2020-11-25T18:31:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\",\"datePublished\":\"2020-11-25T18:31:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","og_description":"LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM \u2013 11:15 AM EST. Dr. Buell will provide an update on clinical programs, including AGEN1181, and corporate progress. Registration for the webinar can be done in advance at https:\/\/wsw.com\/webcast\/evercore11\/register.aspx?conf=evercore11&amp;page=agen&amp;url=https:\/\/wsw.com\/webcast\/evercore11\/agen\/2321775. A replay will be available after the call on the Events &amp; Presentations page of the Agenus website &hellip; Continue reading \"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-25T18:31:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference","datePublished":"2020-11-25T18:31:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","name":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=","datePublished":"2020-11-25T18:31:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQwMyMzODQ0NDU0IzIwMjAwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}